双靶向p38MAPK与MEK抑制破坏间质型胶质母细胞瘤对替莫唑胺的适应性化疗耐药
研究整合激酶组学与药物筛选,发现p38MAPK是间质型胶质母细胞瘤替莫唑胺耐药的关键靶点,耐药细胞通过pH/钙介导的MEK/ERK通路产生适应性耐药;在颅内患者来源异种移植模型中,ralimetinib与binimetinib双抑制可维持原发和复发间质型肿瘤对替莫唑胺的敏感性。
要点
- p38MAPK基因特征可对患者进行分子亚型分层并提供预后价值。
- 间质型细胞通过pH/钙介导的MEK/ERK通路对p38MAPK抑制产生适应性耐药。
- 双靶向p38MAPK与MEK抑制在原发和复发颅内间质型异种移植中维持替莫唑胺敏感性。
核心结论
- 间质型胶质母细胞瘤的替莫唑胺耐药与p38MAPK激活相关;p38MAPK耐药细胞的适应性化疗耐药由MEK/ERK信号介导。
- 双靶向p38MAPK与MEK抑制的辅助治疗可延长替莫唑胺敏感性,有望发展为间质型亚型的精准治疗。
研究设计与样本
- 研究整合患者来源的 proneural 与间质型胶质瘤增殖细胞激酶组学图谱、激酶抑制剂筛选及公共临床数据集,以识别替莫唑胺耐药相关蛋白激酶。
- 采用RNAseq、凋亡实验和彗星实验检测p38MAPK信号与间质型细胞适应性化疗耐药的作用。
- 利用颅内患者来源肿瘤异种移植模型评估ralimetinib(口服活性选择性p38MAPK抑制剂,用于胶质母细胞瘤的I/II期)与binimetinib(已批准用于黑色素瘤的MEK1/2抑制剂,用于高级别胶质瘤的II期)双抑制p38MAPK与MEK/ERK在原发和复发间质型肿瘤中的疗效,重点为生存分析。
主要发现
- 转录组-激酶组整合分析显示p38MAPK为首要靶点,其基因特征可基于分子亚型对患者分层并提供预后价值。
- 老药新用的p38MAPK抑制剂与替莫唑胺协同促进替莫唑胺在细胞内滞留并加剧DNA损伤。
- 间质型细胞通过pH/钙介导的MEK/ERK通路对p38MAPK抑制产生适应性化疗耐药。
- 双靶向p38MAPK与MEK抑制在原发和复发颅内间质型胶质母细胞瘤异种移植中有效维持替莫唑胺敏感性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Precision treatment of glioblastoma is increasingly focused on molecular subtyping, with the mesenchymal subtype particularly resistant to temozolomide. Here, we aim to develop a targeted therapy for temozolomide resensitization in the mesenchymal subtype. METHODS: We integrated kinomic profiles and kinase inhibitor screens from patient-derived proneural and mesenchymal glioma-propagating cells and public clinical datasets to identify key protein kinases implicated in temozolomide resistance. RNAseq, apoptosis assays, and comet assays were used to examine the role of p38MAPK signaling and adaptive chemoresistance in mesenchymal cells. The efficacy of dual p38MAPK and MEK/ERK inhibition using ralimetinib (selective orally active p38MAPK inhibitor; phase I/II for glioblastoma) and binimetinib (approved MEK1/2 inhibitor for melanoma; phase II for high-grade glioma) in primary and recurrent mesenchymal tumors was evaluated using an intracranial patient-derived tumor xenograft model, focusing on survival analysis. RESULTS: Our transcriptomic-kinomic integrative analysis revealed p38MAPK as the prime target whose gene signature enables patient stratification based on their molecular subtypes and provides prognostic value. Repurposed p38MAPK inhibitors synergize favorably with temozolomide to promote intracellular retention of temozolomide and exacerbate DNA damage. Mesenchymal cells exhibit adaptive chemoresistance to p38MAPK inhibition through a pH-/calcium-mediated MEK/ERK pathway. Dual p38MAPK and MEK inhibition effectively maintain temozolomide sensitivity in primary and recurrent intracranial mesenchymal glioblastoma xenografts. CONCLUSIONS: Temozolomide resistance in mesenchymal glioblastoma is associated with p38MAPK activation. Adaptive chemoresistance in p38MAPK-resistant cells is mediated by MEK/ERK signaling. Adjuvant therapy with dual p38MAPK and MEK inhibition prolongs temozolomide sensitivity, which can be developed into a precision therapy for the mesenchymal subtype.
引用
- Cheng HS, Chong YK, Lim EKY, et al. Dual p38MAPK and MEK inhibition disrupts adaptive chemoresistance in mesenchymal glioblastoma to temozolomide. Neuro Oncol. 2024. PMID: 38366847. doi:10.1093/neuonc/noae028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。